GlobeNewswire Inc.··Prokidney Corp.ProKidney Secures $270M Cash Position, Eyes Mid-2027 Approval for Kidney Disease Treatment
ProKidney reports $270M cash reserves extending operations to mid-2027, achieves FDA alignment on accelerated approval pathway for rilparencel with Phase 3 enrollment progressing ahead of schedule.
PROKclinical trialchronic kidney disease